Trans-Pacific Partnership Agreement Hits Turbulence Over Pharma IP Provisions
This article was originally published in PharmAsia News
Executive Summary
The nine countries negotiating the free trade agreement disagree on text for the intellectual property chapter; pharma continues to push for 12 years of biologics data exclusivity while generic associations oppose that and other IP proposals.
You may also be interested in...
Biologics Data Protection In Trade Agreements Becoming Key Focus For PhRMA
At a House hearing PhRMA representative cites the need for 12 years test data exclusivity for biologics in the Trans-Pacific Partnership Agreement. Separately, USTR issues its 2012 Special 301 Report.
Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions
As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.